Evaluation of serum angiopoietin-II in HCV related glomerulonephrities  by Abd-El-Moety, Hoda A. et al.
Alexandria Journal of Medicine (2011) 47, 97–103Alexandria University Faculty of Medicine
Alexandria Journal of Medicine
www.sciencedirect.comORIGINAL ARTICLEEvaluation of serum angiopoietin-II in HCV related
glomerulonephritiesHoda A. Abd-El-Moety *, Gehan H. Magour, Dalia A. Maharem,
Amira M. HusseinMedical Research Institute, Alexandria University, Horria Street, Ibrahimia, Alexandria, EgyptReceived 29 May 2011; accepted 1 July 2011












90-5068 ª 2011 Alexandr
oduction and hosting by Els
er review under responsibilit
edicine.
i:10.1016/j.ajme.2011.07.008





osting by Eª 2011 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. All rights
reserved.1. Introduction
The hepatitis C virus (HCV) is a global health problem. More
than 170 million people world wide are chronically infected
with HCV, which is responsible for over 1 million deaths
resulting from, cirrhosis and liver cancers. The prevalence of
HCV infection varies in different parts of the world, an esti-
mated 4 million Americans have been exposed to HCV repre-
senting approximately 2% of the US population.1,2
Egypt has the highest sero prevalence of HCV reaching up
to 20% in some areas.3,4 About 60–85% of patients infected841451.
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lsevierwith HCV develop chronic hepatitis C, i.e. infection lasting
more than 6 months.5,6
Although the primary burden of disease that is associated
with chronic hepatitis C is liver related, other organ systems
may be involved.2 In the kidney, HCV seems to be strongly
associated with membrano-proliferative glomerulonephritis
(MPGN) usually in the context of cryoglobulinemia, but
MPGN can develop without cryoglobulins in addition to other
types of glomerulonephritis including membranous GN and
focal segmental glomerulosclerosis.7–9
The pathogenesis of hepatitis C-associated renal disease re-
mains incompletely deﬁned, but most evidence suggests that it
is caused by circulating complexes of antibodies and HCV par-
ticles directly causing damage to the kidneys as they are depos-
ited in the glomerulus and tubules of the kidneys.10
Cryoglobulins are antibody complexes that precipitate as
serum is cooled and that dissolve on rewarming.11 HCV is
associated with mixed cryoglobulinemia (MC) type II which
is composed of polyclonal immunoglobulin IgG and monoclo-
nal IgM rheumatoid factor (RF).12 Renal signs of cryogloblin-
emia include proteinuria and microscopic hematuria with mild
to moderate renal in sufﬁciency.13 Other abnormalities include
decreased complement levels and the presence of rheumatoid
factor and cryoglobulins.10
Table 2 Comparison of liver function tests in both groups of
chronic HCV patients.
Group I Group II Z (P)
(n= 24) (n= 16)
ALT (u/l)
Min–max 10.00–216.00 7.00–90.00 0.097
Mean ± SD 36.71 ± 42.27 34.81 ± 25.5 (0.923)
Median 23.00 24.50
AST (u/l)
Min–max 14.00–160.00 12.00–160.00 0.193
Mean ± SD 50.00 ± 31.74 55.19 ± 43.43 (0.847)
Median 44.00 38.50
T. bilirubin
Min–max 0.50–11.80 0.40–16.80 1.216
Mean ± SD 2.51 ± 2.38 3.79 ± 5.68 (0.224)
Median 1.75 1.15
D. bilirubin
Min–max 0.30–8.00 0.10–11.60 0.776
Mean ± SD 1.53 ± 1.70 2.76 ± 4.27 (0.437)
Median 0.90 0.70
T. proteins
Min–max 5.50–8.10 4.00–8.30 1.756
Mean ± SD 6.89 ± 0.63 6.39 ± 1.01 (0.079)
Median 6.85 6.15
S. albumin
Min–max 2.30–5.10 1.90–4.00 2.242
Mean ± SD 3.34± 0.78 2.75±0.58 (0.025)
Median 3.10 2.65
ALP
Min–max 58.00–189.00 59.00–624.00 3.010*
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remains ill deﬁned although it was reported that HCV positive
patients had a 40% higher likelihood for developing renal in
sufﬁciency.14 So, some authors have suggested that screening
for proteinuria and creatinine clearance may be indicated
among patients with chronic HCV.15,16
Angiogenesis, the formation of new vessels, has been re-
ported to play a signiﬁcant role in liver damage-associated
hepatitis C virus infection including hepato cellular carci-
noma.17,18 Angiogenesis is regulated by angiogenic factors,
such as vascular endothelial growth factor (VEGF) and angio-
poietins. Among the known angiogenic factors, VEGF has
emerged as the central regulator of the angiogenic process of
physiological and pathological conditions.19
VEGF is a member of a family of closely related cytokines,
also known as vascular permeability factor. It is highly speciﬁc
mitogen for vascular endothelial cells by binding to two tyro-
sine kinase receptors which are selectively expressed on endo-
thelial cells, it induces endothelial cell proliferation, promotes
cell migration and inhibits apoptosis.20–22
Angiopoietins are a family of vascular growth factors, the
best-studied being angiopoietin 1 (Ang-1) and angiopoietin 2
(Ang-2). They are legends for the tyrosine kinase receptor
Tie 2.23 Angiopoietin 1 (Ang-1) serves as a survival factor
for the endothelium and promotes recruitment of pericytes
and smooth muscle cells, thereby serving to stabilize vascular
networks. Angiopoietin 2 (Ang-2) is a biological antagonist
of Ang-1 and is dramatically expressed at sites of vascular
remodeling. It reduces vascular stability and facilitates access
of VEGF to endothelial cells.19,24,25
1.1. Subjects
The present study included two groups of patients:
Group I: It consisted of 24 patients with chronic hepatitis C
virus without nephropathy.
Group II: It consisted of 16 patients with chronic hepatitis C
virus with nephropathy.
The patients were selected form Medical Research Institute,
Alexandria University. Patients with hepatorenal syndrome,
hepatitis B virus, DM, autoimmune diseases as SLE or malig-
nancies were excluded from the study.
2. Methods
All the studied patients were subjected to the following:
History taking, clinical examination with stress on renal
symptoms as edema of lower limbs, haematuria, oliguria and
association of hypertension together with any other symptoms
related to cryoglobulinemia.Table 1 Sex and age of chronic HCV patients groups
Sex Age (Years) Mean ± SD
M F
Group I 13 11 42.33 ± 9.092
Group II 8 8 51.062 ± 7.57
M=Male; F = Female.
Group I = patients with chronic HCV without nephropathy.
Group II = patients with chronic HCV with nephropathy.Preliminary investigations including fasting serum glucose,
blood urea, serum creatinine, serum uric acid, ALT, AST, total
and direct bilirubin, total proteins, serum albumin, alkaline
phosphatase and gamma glutamyl transferase.26–29 Complete
blood picture, prothrombin activity and INR,30 Rheumatoid
factor, cryoglobulins31–33 and urinary albumin creatinine ratio
were estimated.34,35 Serum levels of vascular endothelial growth
factor (VEGF) and angiopoetin 2weremeasured byELISA.36,37
3. Results
Group I included 13 males and 11 females. Their age ranged
from 29 to 60 years with mean 42.33 ± 9.092 years.
Group II included 8 males and 8 females. Their age ranged
from 34 to 60 years with mean 51.062 ± 7.57 years (Table 1).
Patients in group II showed several manifestations as oede-
ma of lower limbs in nine patients (56.25%), seven patientsMean ± SD 108.08 ± 36.83 204.62 ± 141.52 (0.003)
Median 104.00 162.00
GGT
Min–max 21.00–119.00 16.00–260.00 0.787
Mean ± SD 57.96 ± 28.01 93.12 ± 76.43 (0.431)
Median 51.50 62.00
ALT = Alanine amino transferase; AST = Aspartate amino
transferase; T. bilirubin = Total bilirubin; D. bilirubin = Direct
Brilirubin; T. proteins = Total proteins; S. albumin = Serum
albumin; ALP = Alkaline phosphatase; GGT= Gamma-glutamyl
transferase.
* Statistically signiﬁcant at P 6 0.05. Z for Mann Whitney test.
Table 3 Comparison of Some biochemical parameters in both
groups of chronic HCV patients.
Group I Group II Z (P)
(n= 24) (n= 16)
FBG (mg/dl)
Min–max 84.00–119.00 78.00–115.00 0.843
Mean ± SD 99.83 ± 10.32 101.56 ± 11.89 (0.399)
Median 97.00 105.50
B urea (mg/dl)
Min–max 9.00–48.00 20.00–292.00 2.046*
Mean ± SD 29.916 ± 8.90 78.87 ± 76.56 (0.041)
Median 31.50 45.90
S Creatinine (mg/dl)
Min–max 0.70–1.50 0.80–4.30 2.053*
Mean ± SD 1.121 ± 0.23 1.90 ± 1.105 (0.040)
Median 1.10 1.90
SUA (mg/dl)
Min–max 2.40–7.60 2.60–16.00 2.251*
Mean ± SD 4.98 ± 1.53 7.04 ± 3.29 (0.024)
Median 4.65 7.10
FBG= Fasting blood glucose; B urea = Blood urea; S creati-
nine = Serum creatinine.
SUA= Serum uric acid; Z for Mann Whitney test.
* Statistically signiﬁcant at P 6 0.05.
Table 4 Comparison of Haematological parameters in both
groups of chronic HCV patients.
Group I Group II Z (P)
(n= 24) (n= 16)
Hb
Min–max 6.30–14.10 4.90–14.20 2.144*
Mean ± SD 11.57 ± 2.03 9.82 ± 2.82 (0.032)
Median 11.20 9.20
WBCs
Min–max 2.30–11.70 2.70–18.00 0.700
Mean ± SD 6.01 ± 2.29 6.29 ± 3.99 (0.484)
Median 6.00 5.10
Platelets
Min–max 44.00–301.00 52.00–528.00 0.443
Mean ± SD 165.35 ± 67.97 185.94 ± 114.34 (0.658)
Median 173.00 190.00
Prothrombin
Min–max 40.50–100.00 51.00–100.00 0.758
Mean ± SD 75.18 ± 20.85 82.99 ± 13.70 (0.449)
Median 78.90 85.10
INR
Min–max 1.00–2.40 1.00–2.04 0.444
Mean± SD 1.46±0.50 1.26± 0.25 (0.657)
Median 1.18 1.20
Hb = Haemoglobin; WBCs = white blood cells; INR= Interna-
tional normalized ratio.
Z for Mann Whitney test.
* Statistically signiﬁcant at P 6 0.0.5.
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and four patients had haematuria (25%).Four patients of group I showed arthralgia and one patient
had peripheral neuropathy while ﬁve patients of group II com-
plained of arthralgia.
Renal biopsy was done in ﬁve patients in group II and
showed membranous glomerulonephritis in two patients while
the other three patients had membranoproliferative lesions
(Tables 4 and 5).
Serum albumin was signiﬁcantly lower in group II than
group I and UACR was signiﬁcantly higher in group II than
group I (Table 2).
While blood urea, serum creatinine and serum uric acid
were signiﬁcantly higher in group II than group I (Table 3).
Serum levels of both VEGF and Angio-2 were signiﬁcantly
higher in patients with nephropathy than their levels in those
without nephropathy (Table 6).
There was a signiﬁcant positive correlation between VEGF
and UACR in group I and group II. Also a signiﬁcant negative
correlation between Angio-2 and serum albumin in group I
and a signiﬁcant positive correlation between Angio-2 and
UACR in group II (Tables 7 and 8).4. Discussion
An estimated 12 million Egyptians have been infected with the
hepatitis C virus (HCV), representing approximately 14.7% of
the Egyptian population.38 Although the primary burden of
disease that is associated with chronic hepatitis C is liver re-
lated (liver ﬁbrosis, cirrhosis, and hepatocellular carcinoma),
other organ systems may be involved. In the kidney, HCV
seems to be most strongly associated with membranoprolifer-
ative glomerulonephritis (MPGN) both with and without cry-
oglobulins and membranous glomerulonephritis, although
other types of glomerulonephritis also have been de-
scribed.39–41
The incidence of nephropathy in HCV-infected patients is
unknown, owing to the lack of large-scale ﬁeld studies. An
early study on 188 autopsies with HCV infection42 reported
glomerular lesions in 54.8% of cases, although a cause-and-ef-
fect relationship was not conﬁrmed. In a recent study of renal
biopsies, obtained at the time of liver transplantation from 30
patients with HCV-associated cirrhosis, 25 had immune com-
plex glomerulonephritis. The majority of these patients were
asymptomatic, which suggests that subclinical renal involve-
ment may be highly prevalent among patients with HCV hep-
atitis. The incidence of clinically overt nephropathy was 40%
in our cohort.43
While cryoglobulins and HCV antigen–antibody complexes
are typically blamed in the pathogenesis of HCV nephropathy,
they cannot explain all the reported lesions. Furthermore,
many of the histopathological features of HCV nephropathy
have certain characteristics that distinguish them from other
immune-mediated nephropathies44, which suggest that the
virus may induce renal injury by other, not necessarily im-
mune-mediated mechanisms.45 This goes with our observation
that cryoglobulins were found in only 75% of nephropathic
group.
Angiogenesis has been reported to play a signiﬁcant patho-
genic role to liver damage during CHC.17,18 CHC is associated
with elevated serum levels of angiogenesis markers namely vas-
cular endothelial growth factor (VEGF), angiopoietin 2 (Ang-
2).18 Abnormal angiogenesis also occurs in diabetic nephropa-
Table 5 Comparison of distribution of rheumatoid factor, complement 3, cryoglobulins and values of urinary albumin creatinine
ratio between the two groups of chronic HCV patients.
Group I Group II Test of sig.
(n= 24) (n= 16)
No % No %
RF
ve 14 58.3 7 43.8 X2 = 0.819
+ve 10 41.7 9 56.3 P= 0.366
C3
Low 7 29.2 8 50 X2 = 1.778
Normal 17 70.8 8 50 P= 0.182
Cryoglobulins
ve 20 83.3 12 75.0 FEt = 0.690
+ve 4 16.7 4 25.0
UACR
Min–max 3.90–28.0 90.0–3480.0 Z = 5.304* (<0.001)
Mean ± SD 18.23 ± 5.73 716.94 ± 931.91
Median 18.0 350.0
RF= rheumatoid factor; C3 = complement 3; UACR= urinary albumin creatinine ratio. Z for Mann Whitney test. X2 Chi Square test.
FEt = Fischer Exact test.
* Statistically signiﬁcant at p 6 0.05.
Table 6 Comparison of Angiopoietin-2 and Vascular endothelial growth factor between both groups of chronic HCV patients.
Group I Group II Z (P)
(n= 24) (n= 16)
Angio-2
Min–max 500.00–8805.00 3705.00–150000.00 3.728* (<0.001)
Mean ± SD 4963.96 ± 1881.43 49099.06 ± 41554.27
Median 5047.50 56375.00
VEGF
Min–max 1000.00–6800.00 1060.00–9000.00 2.708* (0.007)
Mean ± SD 2016.75 ± 1446.90 3785.31 ± 2734.19
Median 1430.00 2107.50
Angio-2 = Angiopoietin 2; VEGF= Vascular endothelial growth factor. Z for Mann Whitney test.
* Statistically signiﬁcant at P< 0.01.
Table 7 Correlation between Angiopoietin-2, Vascular endo-
thelial growth factor, albumin and urinary albumin creatinine
ratio in Group I of chronic HCV patients.
Angio-2 VEGF
Albumin r= 0.488* r= 0.363
p= 0.016 p= 0.081
UACR r= 0.288 r= 0.454*
p= 0.172 p= 0.026
Angio-2 = Angiopoietin 2; VEGF= Vascular endothelial growth
factor; r= correlation coefﬁcient; P= signiﬁcance.
* Statistically signiﬁcant at P< 0.05.
Table 8 Correlation between Angiopoietin-2, Vascular endo-
thelial growth factor, albumin and urinary albumin creatinine
ratio in Group II of chronic HCV patients.
Angio-2 VEGF
Albumin r= -0.492 r= 0.041
p= 0.053 p= 0.881
UACR r= 0.829* r= 0.552*
p=< 0.001 p= 0.027
Angio-2 = Angiopoietin 2;VEGF= Vascular endothelial growth
factor; r= correlation coefﬁcient; P= signiﬁcance.
* Statistically signiﬁcant at P< 0.05.
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To the best of our knowledge this is the ﬁrst work investi-
gating the role of VEGF and Ang-2 in pathogenesis of HCV
related nephropathy. We can show that: (1) serum level of both
VEGF and Ang-2 was signiﬁcantly higher in patients withnephropathy (Table 6), (2) there was a signiﬁcant correlation
between serum level of VEGF and UACR, (3) also a signiﬁ-
cant correlation was found between serum levels of Ang-2
and UACR (Tables 7 and 8).
The mechanism of stimulation of VEGF by HCV infection
is through the stabilization of hypoxia-inducible factor 1a
Evaluation of serum angiopoietin-II in HCV related glomerulonephrities 101(HIF-1a). This stabilization is mediated via oxidative stress in-
duced by HCV gene expression. HIF-1a induction in turn led
to the stimulation of vascular endothelial growth factor. It was
showed that HCV-infected cells released angiogenic cytokines,
leading to neovascularization in vivo.46 The signiﬁcantly high-
er level of VEGF in patients with nephropathy denotes that the
source of VEGF in this group is not merely hepatic and sug-
gests a renal contribution. It is noteworthy that many of the
ingredients required for HCV attachment (e.g. glycosamino-
glycans), endocytosis e.g. (LDLr), entry (e.g. SR-B1 and
TLR-3) are abundantly expressed in the renal parenchyma.
In addition, it may be speculated, though yet unproven, that
the virus has the potential of entry and replication in renal tis-
sue if conveyed by infected B-lymphocytes47 or exosomes.48
Previous reports have shown that increased plasma levels of
VEGF may be associated with proteinuria in patients with dia-
betes.49 Our results showed positive correlation between
VEGF and UACR (Tables 7 and 8). Increased VEGF in the
glomeruli may result in proteinuria through two possible dif-
ferent yet closely overlapping or related mechanisms. First,
glomerular VEGF derived from podocytes is involved in the
maintenance of the glomerular endothelium (including main-
taining fenestration) and/or selective permeability to macro-
molecules. High levels of VEGF derived from podocytes can
strongly bind to capillary endothelial cells through speciﬁc
VEGF receptors, which may result in increased permeability
or glomerular hyperﬁltration by altering capillary fenestration
or basement membrane components or indirectly through the
induction of nitric oxide and prostacyclin. Second it has been
reported that VEGF stimulates increased synthesis of collage-
nase by endothelial cells, which result in the proteolytic disrup-
tion of the basement membrane may participate in the
enhancement of proteinuria.50
Elevated expression of Ang-2 was observed in CHC and its
expression is modulated by viral structural proteins.51 Also the
kidney endothelium itself has been identiﬁed as a rich source of
Ang-2, so that chronic organ impairment might directly result
in increased Ang-2 release from the kidney.51,52
Alterations in the expression of the angiopoietins have been
implicated in the progression of diabetic nephropathy.53 In
addition, transgenic mice with inducible overexpression of
angiopoietin-2 in podocytes in otherwise normal healthy adult
animals develop signiﬁcant increases in albuminuria.54 These
observations agree with the positive correlation we found be-
tween circulating angiopoietin level and proteinuria (Tables 7
and 8). These observations raise an important question that
warrants further discussion: How does angiopoietin-2 cause
proteinuria?
Electron microscopic studies in these angiopoietin-2 over-
expressing mice demonstrate glomerular endothelial apoptosis,
but there is no evidence of glomerular capillary collapse or footTable 9 Correlation between Angiopoietin-2 and Vascular
endothelial growth factor in both groups.
Group I Group II
Angio-2 and VEGF r= 0.279 r= 0.390
p= 0.187 p= 0.136
Angio-2 = Angiopoietin 2; VEGF= Vascular endothelial growth
factor; r= correlation coefﬁcient; P= signiﬁcance.process effacement. These ﬁndings are consistent with the role
of angiopoietin-2 in destabilizing endothelial cell integrity55
but raise questions about the mechanism of proteinuria (Table
9).
The authors provide evidence that the slit diaphragm pro-
tein nephrin, an essential component of the glomerular perm-
selectivity barrier, is downregulated in angiopoietin-2
overexpressing mice. On the basis of the observation that pro-
teinuria has been described in the absence of foot process
effacement, the authors argue that these changes in the expres-
sion of nephrin may give rise to a defect in slit diaphragm func-
tion without inducing a structural abnormality in podocytes.54
This is certainly a possibility that might be conﬁrmed by more
detailed ultrastructural analysis of the slit diaphragm. How-
ever, an alternative possibility is that the primary defect in
these mice results from loss of glomerular endothelial
integrity.56
Importantly, the biological effects of angiopoietin-2 are
context dependent and, in vivo, depend on ambient levels of
VEGF-A, such that vessel regression occurs if VEGF-A is
lacking, whereas vessel destabilization followed by angiogene-
sis occurs if the local milieu is rich in VEGF-A.53 It could be
postulated that the increased levels of angiopoietin-2 alongside
a VEGF-A rich milieu in glomeruli will lead to the destabiliza-
tion of blood vessels and hence excessive angiogenesis as what
happens during the initial phases of diabetes.57
5. Conclusions
Circulating levels of the assayed angiogenic factors; VEGF
and Ang-2, are signiﬁcantly higher in patient with HCV
nephropathy than those without nephropathy. The correlation
between circulating levels of VEGF, Ang-2 and UACR a mar-
ker of renal injury points to the potential role of these angio-
genic factors in the pathogenesis of HCV nephropathy.
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